خدا کی بستی-خاندانی رشتوں کے تناظر میں

Shoukat Siddiqui is a prominent name of modern urdu novel. His novels depict the true image of our society. His novel “Khuda Ki Basti” was published in 1959. A lot of research and critical work from social perspective has been done on this novel. Apart from presenting social demerits and moral evils, the story brings into limelight the decadence of marital values and family unity. It skillfully represents that how humility, lowliness and sexual indulgence ruin a family. Since family is an important pillar of a society thus family life affects social values whereas society has a strong impact on the family life. The purpose of this article is to analyze “Khuda Ki Basti” from an outlook of a family life which will definitely highlight some new aspects

Synergistic Effect of Functionalized Nanokaolin Decorated MWCNTs on the Performance of Cellulose Acetate (CA) Membranes Spectacular

In order to enhance salt rejection level and high pressure mechanical integrity, functionalized nanokaolin decorated multiwall carbon nanotubes (FNKM, 0–5 wt % loading) were incorporated into a cellulose acetate (CA) matrix using high temperature solution mixing methodology. Scanning electron microscopy (SEM), X-ray diffraction technique (XRD), thermo-gravimetric analyzer (TGA) and Fourier transform infrared spectrometer (FTIR) were used to characterize the prepared membranes. The obtained results revealed that with increasing FNKM concentration in the host polymeric matrix, composite membrane’s structural, functional, thermal, water permeation/flux and salt rejection characteristics were also modified accordingly. Percent enhancement in salt rejection was increased around threefold by adding 5 wt % FNKM in CA

Characterization of Joint Disease in Women with Hemophilia: The Carriers Ultrasound Project (CUP) Study

Introduction: Women with hemophilia (WWH) are at risk for bleeding despite normal or mildly reduced plasma factor VIII (FVIII) or IX (FIX) activity levels. Subclinical joint bleeds can contribute to longstanding and irreversible joint damage. Although joint health has been well-studied among men with hemophilia, there is currently a gap in knowledge on the prevalence, clinical characteristics, and natural history of joint health in women with hemophilia. No prior studies have utilized point-of-care musculoskeletal ultrasound (POC-MSKUS) to assess the presence and characteristics of joint changes in carrier women. Aim: This multi-institutional, cross-sectional study primarily aimed to evaluate and compare the prevalence and extent of joint-related symptoms and joint changes in WWH compared to age-matched controls utilizing validated clinical tools including the Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) protocol. We also aimed to examine the relationship between innate FVIII and FIX levels and presence of joint disease changes in this population. Methods: Between 2017-2023, women aged 18 to 40 years were enrolled and divided in 2 cohorts. The “carrier cohort” included women with a confirmed hemophilia A or B diagnosis, regardless of factor activity level. The “control cohort” included women without personal or family history of a bleeding disorder. Individuals were excluded if they had history of joint trauma or surgery within 12 months prior to enrollment or any history of joint replacement. Collected clinical information included presence of bleeding symptoms, joint-related symptoms, and historical use of hemostatic medications. Participants underwent clinical and radiological assessment of bilateral elbows, knees, and ankles using the Hemophilia Joint Health Score (HJHS) and HEAD-US protocol. Factor activity levels were measured in the carrier cohort. Descriptive and interferential statistics were performed using SPSS software with p25kg/m2) was significantly associated with an increased prevalence of joint bleeding (25% vs. 0%, p=0.03) among carriers. When dividing carriers in 2 groups based on their baseline factor activity level (>40% versus 40%. There were no changes in mean HJHS or mean HEAD-US scores among the two groups. Conclusions: Women with hemophilia are at increased risk of bleeding manifestations and joint-related symptoms, regardless of factor activity levels. This population also seems to have poorer joint health than do non-carrier women as assessed by HJHS. Dedicated follow-up to help prevent and treat joint-related complications among WWH seems imperative. Our study did not detect significant ultrasonographic joint changes in the carrier cohort. However, joint findings may become more evident later in life or when assessed with magnetic resonance imaging. Further long-term studies are needed to support our hypothesis

Evaluation of BaCo0.Fe-4(0).4Zr0.2-xNixO3-delta perovskite cathode using nickel as a sintering aid for IT-SOFC

In this research work, BaCo0.Fe-4(0).4Zr0.2-xNixO3-delta (x = 0, 0.01, 0.02, 0.03, 0.04) perovskite cathode material for IT-SOFC is synthesized successfully using a combustion method and sintered at low temperature. The effects of nickel as a sintering aid on the properties of BaCo0.Fe-4(0).Zr-4(0).O-2(3-delta) are investigated through different characterization methods. The addition of nickel increased the densification and grain growth at a lower sintering temperature 1200 degrees C. XRD analysis confirms a single phase of BaCo0.Fe-4(0).Zr-4(0).O-2(3-delta), and an increase in crystalline size is observed. SEM micrographs show formation of dense microstructure with increased nickel concentration. TGA analysis revealed that BaCo0.Fe-4(0).4Zr0.2-xNix cathode materials are thermally stable within the SOFC temperature range, and negligible weight loss of 2.3% is observed. The bonds of hydroxyl groups and metal oxides are confirmed for all samples through FTIR analysis. The highest electrical properties are observed for BaCo0.Fe-4(0).4Zr0.2-xNix (x = 0.04) due to increased densification and electronic defects compared to other compositions. The maximum power density of 0.47 W cm(-2) is obtained for a cell having cathode material BaCo0.Fe-4(0).4Zr0.2-xNix (x = 0.02) owing to its permeable and well-connected structure compared to others.Funding Agencies|Laser and Optronics Center (Department of Physics), UET, Lahore, Pakistan</p

Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1-2 trial

Although nitric oxide based therapeutics have been shown in preclinical models to reduce vaso-occlusive events and improve cardiovascular function, a clinical trial of a phosphodiesterase 5 inhibitor increased rates of admission to hospital for pain. We aimed to examine if riociguat, a direct stimulator of the nitric oxide receptor soluble guanylate cyclase, causes similar increases in vaso-occlusive events. This was a phase 1-2, randomised, double blind, placebo-controlled trial. Eligible patients were 18 years or older, had confirmed sickle cell disease documented by haemoglobin electrophoresis or HPLC fractionation (haemoglobin SS, SC, Sβ-thalassemia, SD, or SO-Arab), and stage 1 hypertension or proteinuria. Participants were randomly assigned 1:1 to receive either riociguat or matching placebo via a web-based system to maintain allocation concealment. Both treatments were administered orally starting at 1·0 mg three times a day up to 2·5 mg three times a day (highest tolerated dose) for 12 weeks. Dose escalation by 0·5 mg was considered every 2 weeks if systolic blood pressure was greater than 95 mm Hg and the participant had no signs of hypotension; otherwise, the last dose was maintained. The primary outcome was the proportion of participants who had at least one adjudicated treatment-emergent serious adverse event. The analysis was performed by the intention-to-treat. This trial is registered with ClinicalTrials.gov (NCT02633397) and was completed. Between April 11, 2017, and Dec 31, 2021, 165 participants were screened and consented to be enrolled into the study. Of these, 130 participants were randomly assigned to either riociguat (n=66) or placebo (n=64). The proportion of participants with at least one treatment-emergent serious adverse event was 22·7% (n=15) in the riociguat group and 31·3% (n=20) in the placebo group (difference -8·5% [90% CI -21·4 to 4·5]; p=0·19). A similar pattern emerged in other key safety outcomes, sickle cell related vaso-occlusive events (16·7 [n=11] vs 21·9% [n=14]; difference -5·2% [-17·2 to 6·5]; p=0·42), mean pain severity (3·18 vs 3·32; adjusted mean difference -0·14 [-0·70 to 0·42]; p=0·69), and pain interference (3·15 vs 3·12; 0·04 [-0·62 to 0·69]; p=0·93) at 12 weeks were similar between groups. Regarding the key clinical efficacy endpoints, participants taking riociguat had a blood pressure of -8·20 mm Hg (-10·48 to -5·91) compared with -1·24 (-3·58 to 1·10) in those taking placebo (-6·96 mm Hg (90% CI -10·22 to -3·69; p<0·001). Riociguat was safe and had a significant haemodynamic effect on systemic blood pressure. The results of this study provide measures of effect and variability that will inform power calculations for future trials. Bayer Pharmaceuticals